-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 9.4% in August
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 9.4% in August
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is currently 2.0 days.
Molecular Partners Stock Performance
MOLN opened at $6.21 on Wednesday. Molecular Partners has a one year low of $5.50 and a one year high of $32.04. The company has a fifty day moving average price of $6.33 and a 200-day moving average price of $10.36.
Get Molecular Partners alerts:Molecular Partners (NASDAQ:MOLN – Get Rating) last announced its earnings results on Thursday, August 25th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $12.19 million for the quarter. On average, equities research analysts anticipate that Molecular Partners will post 3.79 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Royal Bank of Canada cut shares of Molecular Partners from an "outperform" rating to a "sector perform" rating in a report on Tuesday, August 30th. SVB Leerink downgraded Molecular Partners from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $30.00 to $8.00 in a research report on Monday, August 29th. Finally, Credit Suisse Group raised Molecular Partners from an "underperform" rating to a "neutral" rating in a research report on Wednesday, May 25th.Institutional Investors Weigh In On Molecular Partners
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its stake in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the period. Federated Hermes Inc. owned about 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. 2.70% of the stock is currently owned by institutional investors and hedge funds.
Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is currently 2.0 days.
分子合夥公司(納斯達克：Moln-Get Rating)是空頭股數8月份股價大幅下跌的接受者。截至8月31日，空頭股數共有26,900股，較8月15日的29,700股下跌9.4%。以日均成交量13,200股計算，目前短息比率為2.0天。
Molecular Partners Stock Performance
分子合作伙伴股票表現
MOLN opened at $6.21 on Wednesday. Molecular Partners has a one year low of $5.50 and a one year high of $32.04. The company has a fifty day moving average price of $6.33 and a 200-day moving average price of $10.36.
Moln週三開盤報6.21美元。分子合夥公司的一年低點為5.50美元，一年高位為32.04美元。該公司的50日移動均線價格為6.33美元，200日移動均線價格為10.36美元。
Molecular Partners (NASDAQ:MOLN – Get Rating) last announced its earnings results on Thursday, August 25th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $12.19 million for the quarter. On average, equities research analysts anticipate that Molecular Partners will post 3.79 EPS for the current fiscal year.
分子合夥公司(納斯達克：Moln-Get Rating)最近一次公佈財報是在8月25日(星期四)。該公司公佈了該季度每股收益(EPS)(0.15美元)。該業務本季度的收入為1219萬美元。平均而言，股票研究分析師預計分子合夥公司本財年的每股收益將達到3.79股。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Institutional Investors Weigh In On Molecular Partners
機構投資者看好分子合夥人
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its stake in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the period. Federated Hermes Inc. owned about 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. 2.70% of the stock is currently owned by institutional investors and hedge funds.
一家機構投資者最近提高了對分子合夥公司股票的頭寸。聯合愛馬仕公司最近提交給美國證券交易委員會(美國證券交易委員會)的文件顯示，今年第一季度，該公司增持分子合夥公司股份94.2%。在此期間，該公司額外購買了221,743股，持有該公司457,037股股票。在最近一次報告期結束時，聯合愛馬仕公司擁有分子夥伴公司約1.41%的股份，價值9,264,000美元。2.70%的股票目前由機構投資者和對衝基金持有。
Molecular Partners Company Profile
分子合作伙伴公司簡介
(Get Rating)
(獲取評級)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子夥伴公司是一家臨牀階段的生物製藥公司，專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar，該藥物處於第三階段臨牀試驗；以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- 免費獲取StockNews.com關於分子夥伴的研究報告(Moln)
- 3家航空公司股票陷入持有格局
- Roku股票下跌，但並未出局
- 福特在第三季度發出警告後是否正在反彈
- 如果你渴望價值，那就嚐嚐露絲的好客之道吧
- AMD股票是不是跌得太厲害了？
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收分子合作伙伴和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧